Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lactobacillus rhamnosus IDCC 3201 tyndallizate
- Development stage
- Unknown
- Lead developer
- Ildong Bioscience
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral
01
Overview
Lactobacillus rhamnosus IDCC 3201 tyndallizate (RHT3201) is a postbiotic developed by Ildong Bioscience, consisting of heat-killed (tyndallized) bacterial cells from the strain *Lacticaseibacillus rhamnosus IDCC 3201*. [1] It functions as an immunomodulator by improving the balance between Th1 and Th2 immune responses. [12] The mechanism involves down-regulating type 2 helper T (Th2) cytokines like IL-4 and IL-31 while up-regulating type 1 helper T (Th1) cytokines such as IL-12 and IFN-γ, which leads to a reduction in serum immunoglobulin E (IgE) levels. [12, 14, 15] It has been clinically investigated for the treatment of atopic dermatitis in children, where it demonstrated significant improvements in SCORAD scores. [8, 9] It is also being studied for its benefits in gastrointestinal health. [2] RHT3201 has been approved in Korea as a 'Functional Ingredient for Health Functional Foods' for skin health and received a letter of no objection as a New Dietary Ingredient (NDI) from the U.S. FDA. [1, 7]
- Brand names
- gQlab Postbiotics RHTRHT3201RHT-3201RHT 3201
- Other names
- tyndallized Lactobacillus rhamnosus IDCC 3201heat-killed Lacticaseibacillus rhamnosus IDCC 3201
02
Targets
IL12 (Interleukin-12)IFNG (Interferon gamma)IL-4 (Interleukin 4)IL31 (IL-31)
Beyond the preview
Go deeper on Lactobacillus rhamnosus IDCC 3201 tyndallizate.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Lactobacillus rhamnosus IDCC 3201 tyndallizate.